Joseph Rudick, M.D.
Dr. Albert Joseph Rudick is a Senior Scientific Advisor at Brookline. He has been a partner of Associate Ophthalmologists P.C., a private ophthalmology practice located in New York. Dr. Rudick was a co-founder of biotechnology company Effective Pharmaceuticals, Inc., licensee of Trimestra™ (oral estriol). He served as Chief Medical Officer and as a Member of The Board of Directors of Synthetic Biologics. Dr. Rudick was also a co-founder, CEO and President and a member of The Board of Directors of Atlantic Technology Ventures, Inc. (now TG Therapeutics, Inc). While at Atlantic, he structured a corporate partnership with Bausch & Lomb for development of Atlantic's novel cataract removal device, named Catarex™, as well as a partnership with Indevus Pharmaceuticals, Inc. for development of a novel clinical-stage neuropathic pain compound, known as IP-571. Dr. Rudick served as a Vice President of Paramount BioCapital, Inc., where he participated in numerous technology inlicensing transactions and private equity financings. At Brookline, Dr. Rudick focuses on PIPE and private placement transactions.
Dr. Rudick earned a B.A. in Chemistry, with the distinction of Phi Beta Kappa, from Williams College and a Doctorate of Medicine, with the distinction of Alpha Omega Alpha, from the University of Pennsylvania.